RIPK1 and early-onset autosomal dominant Alzheimer disease: Our data are also translationally important because it suggests that pharmacologically inhibiting necroptosis could be an effective strategy to reduce inflammaging and age‐related diseases in which chronic inflammation plays a role, for example, cancer, Alzheimer’s disease, cardiovascular disease, etc. Currently, therapeutic applications of RIPK1 inhibitors for the treatment of a variety of human diseases are being tested in clinical trials (Mifflin et al., 2020).